<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Inaugural Symposium:

Advancing Drug Discovery for Oncology

Date: Wednesday, November 9, 2022 | 9:00am - 1:00pm

Location: San Francisco Airport Marriott Waterfront, Meeting Room San Ramon

The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.

With the expansion of Immuno-Oncology (I/O) drug development, effective preclinical I/O platforms are required for testing efficacy and safety of new I/O targets. Finally, a diversity of clinically-predictive in vivo models are needed to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations before entering the clinic.

This symposium will bring together R&D and preclinical teams from pharmaceutical and biotech companies to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches.

Register Now

Registration for the event is required. Attendance for the symposium is free and lunch will be served, but spaces are limited. We encourage you to register early. 


Sumithra Urs Ph.D.

Director, Scientific Engagement, Crown Bioscience

Talk Title: Identifying Clinical Candidates with Cancer Organoids

Nichole Escalante

Scientist, Zymeworks Inc.

Talk Title: Engineering IL-12 for Tumor Specific Cytotoxicity

Cecelia Pearson

Senior Scientist II at Bolt Biotherapeutics, Inc.

Talk Title: Immune-stimulating antibody conjugates: Harnessing the innate and adaptive immune systems to target solid tumors

Gayathri Swaminath Ph.D., MBA

Vice President Research &
Development, Greenfire Bio

Talk Title: GRN300 a Novel Orally Bioavailable SIK2 and SIK3 Inhibitor Addresses Chemoresistance in Combination with Chemotherapy and PARP inhibitors (Zoom)

Share This


Your privacy is important to us.
We'll never share your information.

Attend Our SoCal Symposium